Stocks · Health care · Biological Products, (No Diagnostic Substances)

Maze Therapeutics, Inc.

MAZE Clue Score57
United States Fiscal year ends December CIK 0001842295 Results filed 11 Aug 2026

What the insiders did Mostly scheduled

By person

10 insiders · 102 transactions

There is no salary here to measure against. Maze Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Harold Bernstein
President, R&D & CMO
—
$9.46M (30) scheduled
−$9.46M
0
0.0000%
$0.00
—
Jason Coloma V
Chief Executive Officer
—
$7.23M (29) scheduled
−$7.23M
482,491
0.8686%
$14.98M
−30.7%
Atul Dandekar
Csbo
—
$5.46M (22) scheduled
−$5.46M
32,316
0.0582%
$1.00M
+170.5%
Amy Bachrodt
SVP, Finance
—
$1.56M (13) scheduled
−$1.56M
12,965
0.0233%
$402.60K
0.0%
Catherine A. Sohn
Director
—
$1.15M (2) scheduled
−$1.15M
0
0.0000%
$0.00
—
Phillips Courtney
GC and Corp. Secretary
—
$104.77K (4)
−$104.77K
7,007
0.0126%
$217.59K
—
Third Rock Ventures IV, L.P. entity
10% owner
—
—
—
5,424,758
9.77%
$168.45M
+1,643%
Jonathan E Lim
Director
—
—
—
307,956
0.5544%
$9.56M
—
Charles J Homcy
Director
—
—
—
38,535
0.0694%
$1.20M
+7.2%
Richard H Scheller
Director
—
—
—
0
0.0000%
$0.00
−100.0%